Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet
Por um escritor misterioso
Descrição
Rationale and design of the AXIOMATIC-SSP phase II trial
Full article: New pharmacotherapeutic options for oral
Full article: New pharmacotherapeutic options for oral
JCDD, Free Full-Text
PDF) Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke
Full article: Atrial fibrillation and stroke
Design and Preclinical Characterization Program toward Asundexian
JCDD, Free Full-Text
Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
PDF) Pharmacological targets of Asundexian relevant to its
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
Safety of the oral factor XIa inhibitor asundexian compared with
Anticoagulation
de
por adulto (o preço varia de acordo com o tamanho do grupo)